2025-09069Notice

Draft Guide Helps Speed Generic Psoriasis Cream Approvals

Published Date: 5/21/2025

Notice

Summary

The FDA just released a draft guide to help drug makers test roflumilast cream, a medicine for skin problems. This guide shows how to prove new versions work just as well as the original, making it easier and faster to get approval. If you’re in the drug business, keep an eye out—final rules could speed up your product launches and save money!

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Draft FDA Guidance for Roflumilast

The FDA released a draft guidance titled "Draft Guidance on Roflumilast." When finalized, it will provide product-specific recommendations on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for roflumilast topical cream.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
5/21/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in